HER2 testing for breast carcinoma: Recommendations for rapid diagnostic pathways in clinical practice

Journal of Clinical Pathology

Volumn 67, Issue 2, 2014, Pages 161-167

  Shaaban, Abeer M ^a   Purdie, C A ^b   Bartlett, J M S ^c   Stein, R C ^d   Lane, S ^a   Francis, A ^e   Thompson, A M ^f   Pinder, S E ^g  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ARTICLE; BIOPSY; BREAST CARCINOMA; CANCER DIAGNOSIS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; EXCISION; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT CARE; PRIORITY JOURNAL; TUMOR CELL; TURNAROUND TIME;

EID: 84893656079     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201819     Document Type: Article

References (22)

1. Bartlett JM, Starczynski J, Atkey N, et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 2011;64:649-53.
2. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008;61:818-24. (Pubitemid 351969725)
3. Verma R, Bowen RL, Slater SE, et al . Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. Br Med Bull 2012;103:129-45.
4. Purdie CA, Baker L, Ashfield A, et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer 2010;103:475-81.
5. NCCN guidelines. NCCN clinical practice guidelines in Oncology (NCCN Guidelines) breast cancer: National Comprehensive Cancer Networ. 2011.
6. NHS Cancer Screening Programmes and the Royal College of Pathologists. Pathology reporting of Breast disease. 2005;Publication no 58 NHSBSP.
7. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33. (Pubitemid 46121873)
8. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
9. Criscitiello C, Azim HA Jr, Agbor-Tarh D, et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol 2013;24:1980-5.
10. National Cancer Action Team. National Cancer Peer Review Programme Report 2010/2011. An overview of the findings from the 2010/2011 National Cancer Peer Review of Cancer Services in England. 2011.
11. Roche. Integration of HER2 result in MDT audit. Data on file. HER2020. 2008.
12. Purdie CA, Jordan LB, McCullough JB, et al . HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 2010;56:702-7.
13. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-82. (Pubitemid 29318824)
14. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-23. (Pubitemid 36411217)
15. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3-11. (Pubitemid 41355986)
16. Mueller-Holzner E, Fink V, Frede T, et al. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 2001;69:13-19. (Pubitemid 33079025)
17. Arnedos M, Nerurkar A, Osin P, et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009;20:1948-52.
18. Lee AH, Key HP, Bell JA, et al. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. Histopathology 2012;60:880-4.
19. van de Ven S, Smit VT, Dekker TJ, et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011;37:422-30.
20. National Institute for Health and Clinical Excellence. Breast Cancer Quality Standard. 2011.
21. Association of Breast Surgery at BASO. Surgical guidelines for the management of breast cancer. Eur J Surg Oncol 2009;35(Suppl 1):1-22.
22. Kosa C, Kardos L, Kovacs J, et al. Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment. Pathol Res Pract;209:147-50.